COVID-19 severity in asthma patients: A multi-center matched cohort study

Objective: The evidence pertaining to the effects of asthma on Coronavirus disease 2019 outcomes has been unclear. To improve our understanding of the clinically important association of asthma and Coronavirus disease 2019. Methods: A matched cohort study was performed using data from the Mass General Brigham Health Care System (Boston, MA). Adult (age [≥] 18 years) patients with confirmed Coronavirus disease 2019 and without chronic obstructive pulmonary disease, cystic fibrosis, or interstitial lung disease between March 4, 2020 and July 2, 2020 were analyzed. Up to 5 non-asthma comparators were matched to each asthma patient based on age (within 5 years), sex, and date of positive test (within 7 days). The primary outcomes were hospitalization, mechanical ventilation, and death, using multivariable Cox-proportional hazards models accounting for competing risk of death, when appropriate. Patients were followed for these outcomes from diagnosis of Coronavirus disease 2019 until July 2, 2020. Results: Among 562 asthma patients, 199 (21%) were hospitalized, 15 (3%) received mechanical ventilation, and 7 (1%) died. Among the 2686 matched comparators, 487 (18%) were hospitalized, 107 (4%) received mechanical ventilation, and 69 (3%) died. The adjusted Hazard Ratios among asthma patients were 0.99 (95% Confidence Internal 0.80, 1.22) for hospitalization, 0.69 (95% Confidence Internal 0.36, 1.29) for mechanical ventilation, and 0.30 (95% Confidence Internal 0.11, 0.80) for death. Conclusions: In this matched cohort study from a large Boston-based healthcare system, asthma was associated with comparable risk of hospitalization and mechanical ventilation but a lower risk of mortality.

[1]  J. Wisnivesky,et al.  Asthma in COVID-19 Hospitalizations: An Overestimated Risk Factor? , 2020, Annals of the American Thoracic Society.

[2]  M. Humbert,et al.  Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation , 2020, European Respiratory Journal.

[3]  J. Boyce,et al.  Risk factors for hospitalization, intensive care, and mortality among patients with asthma and COVID-19 , 2020, Journal of Allergy and Clinical Immunology.

[4]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[5]  A. Peters,et al.  Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19 , 2020, Journal of Allergy and Clinical Immunology.

[6]  A. Ryo,et al.  Molecular pharmacology of ciclesonide against SARS-CoV-2 , 2020, Journal of Allergy and Clinical Immunology.

[7]  M. Butler,et al.  Prevalence of comorbid asthma in COVID-19 patients , 2020, Journal of Allergy and Clinical Immunology.

[8]  N. Kaminski,et al.  Expression of SARS-CoV-2 receptor ACE2 and coincident host response signature varies by asthma inflammatory phenotype , 2020, Journal of Allergy and Clinical Immunology.

[9]  E. Taioli,et al.  The Impact of Asthma on Mortality in Patients With COVID-19 , 2020, Chest.

[10]  L. Liang,et al.  Association of asthma and its genetic predisposition with the risk of severe COVID-19 , 2020, Journal of Allergy and Clinical Immunology.

[11]  J. Stingone,et al.  Asthma among hospitalized patients with COVID-19 and related outcomes , 2020, Journal of Allergy and Clinical Immunology.

[12]  Supinda Bunyavanich,et al.  Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults. , 2020, JAMA.

[13]  D. Halpin,et al.  Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective , 2020, European Respiratory Journal.

[14]  Nathaniel Hupert,et al.  Clinical Characteristics of Covid-19 in New York City , 2020, The New England journal of medicine.

[15]  Jing Shi,et al.  Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan , 2020, Journal of Allergy and Clinical Immunology.

[16]  D. Halpin,et al.  Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? , 2020, The Lancet Respiratory Medicine.

[17]  Fabian J Theis,et al.  SARS-CoV-2 Receptor ACE2 is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Enriched in Specific Cell Subsets Across Tissues , 2020, SSRN Electronic Journal.

[18]  H. Momma,et al.  Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells , 2020, Respiratory Investigation.

[19]  C. Akdis,et al.  Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China , 2020, Allergy.

[20]  W. Glasheen,et al.  Charlson Comorbidity Index: ICD-9 Update and ICD-10 Translation. , 2019, American health & drug benefits.

[21]  Z. Memish,et al.  Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission , 2018, The Lancet Infectious Diseases.

[22]  R. Wunderink,et al.  MERS, SARS and other coronaviruses as causes of pneumonia , 2017, Respirology.

[23]  William W Busse,et al.  Role of viral respiratory infections in asthma and asthma exacerbations , 2010, The Lancet.

[24]  Henry C. Chueh,et al.  Calculating the Benefits of a Research Patient Data Repository , 2006, AMIA.

[25]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.